Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 41 of 43

Gaps in Knowledge (1 of 2)

The effectiveness review revealed areas where the evidence about the effectiveness of first-generation (FGAs) and second-generation (SGAs) antipsychotics in treating pediatric psychiatric disorders is limited or absent, including:

  • Few head-to-head comparisons of FGAs and SGAs exist, either within or between classes, to demonstrate their effectiveness, benefits, and adverse effects for use in pediatric and young adult populations.
  • No studies were found that reported pediatric use of antipsychotics to treat obsessive-compulsive disorder, post-traumatic stress disorder, or anorexia nervosa.
  • Studies of young adults (ages 19–24) were rare.
  • Few studies reported outcomes that are important to patients (e.g., health-related quality of life, school performance, and legal interactions), and there is no consensus on the minimal clinically important effects to be produced by treatments.